Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Strong free cash flow, secular tailwinds, and low valuations make Cigna financially attractive. Returns in about 1 - 1.5 years are expected in the range of 40-50% with subsequent long-term compounding in line with historic 12-14%.

Unpopular Cigna May Become Very Rewarding

Cigna (CI) expands ACA offering in additional counties across North Carolina with enhanced benefits.

Cigna (CI) Expands Presence on Exchanges in North Carolina (Revised)

Cigna (CI) is providing Medicare Advantage business in 63 new counties within the state of North Carolina.

Cigna (CI) Extends Medicare Advantage in North Carolina

Avenir Capital recently released its Q3 2020 Investor Letter, a copy of which you can download here. The Avenir Global Fund (the “Fund”) increased 8.7% for the September 2020 quarter bringing the past 1-year return to –3.9% (net). The MSCI ACWI index (AUD) returned 3.9% for the quarter and the same for past year. You should check out Avenir Capital's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Is Cigna (CI) a Smart Long-term Buy?

Athene Holding Ltd. Class A

Centene

Alphabet

JPMorgan Chase & Co

Leon Cooperman (Trades, Portfolio), founder and chairman of the Omega Advisors Family Office, disclosed that its top five trades for the third quarter included new holdings in Alphabet Inc. (NASDAQ:GOOG)(NASDAQ:GOOGL) and Athene Holding Ltd. (NYSE:ATH) and sells in JPMorgan Chase & Co. (NYSE:JPM), Centene Corp. (NYSE:CNC) and Cigna Corp. (NYSE:CI).

Leon Cooperman's Top 5 Trades of the 3rd Quarter

Report explores the impact of workplace wellness programs; alongside expert insights into how to deliver effective initiatives and measure return on investment (ROI) HONG KONG, Nov. 12, 2020 /PRNewswire/ -- Cigna (NYSE:CI) International Markets and Asia Care Group, a leading international...

Positive Impact of Workplace Health & Well-being Programs Highlighted by Cigna Study

Amgen

AbbVie

Anthem

Bristol-Myers

As Mr. Valuation, I find myself constantly reminding investors that value investing requires patience. However, value investing also requires the willingness to get your money in front of attractive valuation when it is discovered. Trying to time your purchases perfectly can just as easily cause you to miss out on significant gains as it is to participate in them. More directly stated, significant undervaluation can stimulate strong pent-up demand causing stock prices to rise rapidly. Therefore, if you are not already in front of those advances, you can miss out on a lot of profit and opportunity.

5 Leading Healthcare Stocks Surging On Pent-Up Demand

Cigna's (CI) prolific business profile and a solid balance sheet position poise it well for long-term growth.

Cigna (CI) Rides on a Diversified Business, Capital Position

Cigna Corporation's (CI) CEO David Cordani on Q3 2020 Results - Earnings Call Transcript

Cigna's (CI) Q3 results reflect a strong fundamental performance across its businesses besides the return of medical utilization to more typical levels and COVID-19-related adversities.

Cigna (CI) Q3 Earnings & Revenues Beat Estimates, Grow Y/Y

Cigna profits were up slightly in the third quarter as patients who put off medical care treatment began to return to healthcare services at levels prior to the onset of the Covid-19 pandemic.

Cigna Patients Returning To Care At More ‘Typical Levels' In Pandemic

Shares of Cigna Corp. edged up 0.2% in premarket trading Thursday, after the health insurer reported third-quarter profit and revenue that beat expectations, while providing an in-line full-year outlook, boosted by the return of medical utilization to more typical levels and COVID-19-related impacts. Net income rose to $1.39 billion, or $3.78 a share, from $1.35 billion, or $3.57 a share, in the year-ago period.

Cigna's stock edges up after profit and revenue beats, in line outlook

BLOOMFIELD, Conn., Nov. 5, 2020 /PRNewswire/ -- Total revenues in the third quarter were $41.0 billion. Adjusted revenues1 were $40.8 billion. Shareholders' net income for the third quarter was $1.4 billion, or $3.78 per share Adjusted income from operations2 for the third quarter was...

Cigna Reports Third Quarter 2020 Performance, Raises Revenue Guidance

Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.

Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?

Biogen

Johnson & Johnson

Eli Lilly

Merck

UnitedHealth Group

Shares of UnitedHealth Group Inc. soared 10.2% in morning trading, enough to pace the Dow Jones Industrial Average's gainers, as the uncertain election outcome is seen as a boon to the health care sector. The stock's price gain of $32.65 was adding about 215 points to the Dow's price, while the Dow was up 547 points, or 2.0%.

Health care stocks soar, add more than 350 points to the Dow's price

CVS Health

These three medical insurance stocks all trade for 14 times earnings or less, and they pay dividends.

3 Medical Insurance Stocks You Can Buy On Sale Right Now

CNO Financial Group

Horace Mann Educators

MetLife

MGIC Investment

Old Republic International

6 Multiline Insurers to Watch Out for Amid Operational Challenges

LONDON--(BUSINESS WIRE)--AM Best has assigned a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of “a” to CIGNA Global Insurance Company Limited (CGIC) (Guernsey). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect CGIC's balance sheet strength, which AM Best categorises as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management. Furthermore, the ratings of

AM Best Assigns Credit Ratings to CIGNA Global Insurance Company Limited

Cigna (CI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Cigna (CI) Now

Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Cigna (CI) Keep the Earnings Surprise Streak Alive?

Cigna (CI) closed at $181.88 in the latest trading session, marking a -1.41% move from the prior day.

Cigna (CI) Stock Moves -1.41%: What You Should Know

Cigna's (CI) Medicare Advantage expansion in new counties and states with attractive prices and a suite of product and service offerings holds promise to widen its market share.

Cigna Set to Grab a Bigger Pie of Medicare Advantage Business

DALLAS, Oct. 13, 2020 /PRNewswire/ -- Cigna (NYSE:CI) has named Keith Barnes as market president for its commercial health care and related benefits plans in North Texas and Oklahoma. In this role, his responsibilities include driving market growth by creating customer value and ensuring...

Keith Barnes Named Market President for Cigna's Commercial Business in North Texas and Oklahoma

HONG KONG, Oct. 13, 2020 /PRNewswire/ -- Cigna's (NYSE:CI) International Markets business today published the third edition of its COVID-19 Global Impact Study, which sheds new light on the impact of the virus on global perceptions of health and well-being. The report reveals that:...

Cigna's Latest Cigna COVID-19 Study Reveals Widespread Financial Anxiety

Apple

Alibaba

Canopy Growth

Walgreens

Investors have these seven election stocks to consider avoiding, as uncertainties grow in the near-term and market selling rises. The post 7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote appeared first on InvestorPlace.

News for Cigna Stock (CI)